IP Library › Granted Patent US 12,509,487
Granted Patent B2
US 12,509,487 · App. 18/091,431 · Granted Dec 30, 2025

Neurosteroid compounds and methods for their preparation and use in treating central nervous system disorders

Inventor: Doodipala Samba Reddy (Bryan, TX)
Assignee: THE TEXAS A&M UNIVERSITY SYSTEM
C07J43/003A61P25/08C07J5/0015C07J41/0088
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,509,487
App. No.
18/091,431
Granted
Dec 30, 2025
Kind
B2
Abstract

Described herein is the chemical structure of neurosteroid derivative compounds, methods of synthesizing the derivatives, and their uses in treating disorders, including those of the central nervous system. These compounds are readily synthesized and have improved pharmaceutical properties, including water solubility, compared to known neurosteroids.

Claims (25)

1 . A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2 . The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

3 . The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

4 . The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

5 . The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

6 . The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

7 . The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

8 . The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

9 . The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

10 . The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

11 . The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof; or the compound is:

or a pharmaceutically acceptable salt thereof.

12 . A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

13 . The pharmaceutical composition of claim 12 , wherein said pharmaceutically acceptable carrier is a cream, gel, liposome, nanoparticle, ointment, polymeric micelle, protein, or a microsphere.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 30, 2022
From: REDDY, DOODIPALA SAMBA
To: THE TEXAS A&M UNIVERSITY SYSTEM
Reel/Frame 062242/0285 →
Continuity (3)
Continuation 17049976
Provisional Application 62661187 · Apr 23, 2018
Related Publication 20230151052A1 · May 18, 2023
References Cited (8)
US 11542296B2 · Reddy · 2023 [cited by applicant]
WO WO9303732 · 1993 [cited by applicant]
WO WO9427608 · 1994 [cited by applicant]
WO WO9616076 · 1996 [cited by applicant]
Chuang, S.-H., et al. “3β-Methyl-Neurosteroid Analogs Are Preferential Positive Allosteric Modulators and Direct Activators of Extrasynaptic δ-Subunit γ-Aminobutyric Acid Type A Receptors in the Hippocampus Dentate Gyru… [cited by applicant]
Hogenkamp, D. J. et al. “Pharmacological profile of a 17β-heteroaryl-substituted neuroactive steroid” [cited by applicant]
Written Opinion in International Application No. PCT/US2019/028755, Oct. 1, 2019, pp. 1-7. [cited by applicant]
Carver, C. M. et al. “Neurosteroid Structure-Activity Relationships for Functional Activation of Extrasynaptic OGABAA Receptors” J Pharmacol Exp Ther., Apr. 2016, pp. 188-204, vol. 357. [cited by applicant]